FindTrial
Sign In

Study the efficacy between Palashpushpa Rasakriya Anjana And Triphala Rasakriya Anjana In The Management Of Seborrhoeic Blepharitis.

A Randomized Controlled Clinical Trial To Compare The Efficacy Between Palashpushpa Rasakriya Anjana And Triphala Rasakriya Anjana In The Management Of Seborrhoeic Blepharitis.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/04/032879
Enrollment
60
Registered
2021-04-16
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: H010- Blepharitis

Interventions

Intervention1: Palashpushpa Rasakriya Anjana: Group A 30 patients will be treated with Palashpushpa Rasakriya Anjana. Varti will be prepared of 1 harenu matra(approx 50mg) for local application, for 7

Sponsors

PDEAs College of Ayurveda And Research Centre Akurdi Pune
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: i.Patient from age group of 18-60 years irrespective of gender, religion, occupation. ii. Patient having signs and symptoms of Seborrhoeic Blepharitis like- • Itching • Lid edema • Watering of eyes • Redness • Whitish scales at the lid margin

Exclusion criteria

Exclusion criteria: i. Recently eye surgeries done like cataract, pterygium, chalazion ii. All active infectious diseases of eyelid like stye, chalazion iii. Known lid malignancy like papillomas, xanthelasma iv. One eyed patient. v. Patient showing signs and symptoms of Covid19

Design outcomes

Primary

MeasureTime frame
To compare and study the efficacy between â?? Palashpushpa Raskriya Anjanaâ?? , once in a day for 15 consecutive days and â??Triphala Rasakriya Anjanaâ??, once in a day for 15 consecutive days in the management of Seborrhoeic Blepharitis.â??Timepoint: Follow up on every 7th day (7th, 15th ) Total follow ups with window period of 7 days—

Secondary

MeasureTime frame
To observe adverse effect of drug, if anyTimepoint: Follow up on every 7th day (7th, 15th ) Total follow ups with window period of 7 days—

Countries

India

Contacts

Public ContactDr Manisha Pingale

PDEAs College of Ayurveda And Research Centre Akurdi Pune

manishapingale999@yahoo.in9850160353

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026